Fly News Breaks for July 15, 2019
Jul 15, 2019 | 09:38 EDT
Roth Capital analyst Darren Aftahi notes that privately-held Sharecare, which he estimates Remark Holdings (MARK) owns about 4.5% of, recently announced Quest Diagnostics (DGX) as its preferred laboratory partner, with Quest also making a strategic investment in the company. The analyst believes this could set the stage for a potential IPO going forward. Based on his current analysis, Aftahi thinks Remark's stake is worth about $150M-$175M, implying about $3.65-$4.31/share, multiples of its current $43M value. A liquidity event in Sharecare would help to much better capitalize Remark's AI business, he contends. The analyst reiterates a Buy rating and $7.50 price target on Remark's shares.
News For MARK;DGX From the Last 2 Days
Jan 19, 2022 | 08:45 EST
Latest data shows the largest indicative borrow rate increases among liquid option names include: CF Acquisition Corp (CFVI) 2.86% +1.43, Concord Acquisition Corp (CND) 12.58% +1.17, Evofem Biosciences (EVFM) 22.52% +0.89, Genprex (GNPX) 46.06% +0.52, Matterport (MTTR) 36.03% +0.47, Shell Midstream (SHLX) 1.95% +0.45, Remark Media (MARK) 8.61% +0.45, Tattooed Chef (TTCF) 15.12% +0.37, Taseko Mines (TGB) 1.70% +0.25, and EVgo (EVGO) 18.21% +0.22.